|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we found that Med19 was obviously elevated in human breast cancer tissues, which was significantly associated with larger tumors, high-grade malignant features and poor prognosis.
|
30583076 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional assays showed that knocking-down of Med19 can suppress cell proliferation and migration in T24, UM-UC3 cells and 5637 in vitro, and inhibited BCa tumour growth in vivo.
|
28631286 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
|
27811858 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, Med19 knockdown significantly suppressed tumour growth in an OS xenograft nude mouse model via suppression of cyclin D1 and cyclin B1.
|
24565852 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Med19 was related to tumor growth of BCa.
|
23276457 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Med19 was associated with tumor size, cancer cell differentiation, and TNM stages (P<0.05).
|
22565189 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MED19 RNAi significantly inhibited ovarian cancer tumor growth in engrafted nude mice.
|
22961438 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the inhibition of Med19 by RNAi dramatically reduced hepatocellular carcinoma cell proliferation, induced cell-cycle arrest in the G(0)/G(1) phase, and suppressed tumor formation.
|
21372827 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Med19 expression was significantly associated with tumor grade (p = 0.026).
|
20890603 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The in vitro prostate cancer cell proliferation, colony formation, and in vivo tumor growth in nude mice xenografts was significantly reduced after the downregulation of MED19.
|
21871180 |
2011 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our previous study found that mediator complex subunit 19 (Med19) is upregulated and involved in breast cancer tumorigenesis; however, the detailed effects and mechanism of Med19 in breast cancer require further study.
|
30583076 |
2019 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
The present study identified Tspan8 as the first LCMR1 target that could explain its function in carcinogenesis.
|
27375018 |
2017 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
28337304 |
2017 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
25735376 |
2015 |
|
Carcinogenesis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
The effect of downregulation of LCMR1 by lentivirus-mediated small hairpin RNA (shRNA) on CRC cell proliferation and tumorigenesis was explored.
|
21732059 |
2012 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
These results provide new evidence of an important role for Med19 in the development of hepatocellular carcinomas, suggesting that lentivirus-mediated RNAi to target Med19 is a potential tool for inhibiting cancer cell proliferation and tumorigenesis.
|
21372827 |
2011 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
To tested the functional role of MED19 in human prostate cancer, we downregulated MED19 expression in prostate cancer cells (PC-3 and DU145) by lentivirus-mediated short hairpin (shRNA), and analyzed the effect of inhibition of MED19 on prostate cancer cell proliferation and tumorigenesis.
|
21871180 |
2011 |
|
Carcinogenesis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
MED19 promotes proliferation and tumorigenesis of lung cancer.
|
21519921 |
2011 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
28337304 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Including BC-associated SNPs in risk assessment can provide more accurate risk prediction than family history alone and can influence recommendations for cancer screening and prevention modalities for high-risk women.Genet Med 19 1, 30-35.
|
27171545 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Including BC-associated SNPs in risk assessment can provide more accurate risk prediction than family history alone and can influence recommendations for cancer screening and prevention modalities for high-risk women.Genet Med 19 1, 30-35.
|
27171545 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
28337304 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
25735376 |
2015 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis.
|
25735376 |
2015 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The data showed that the expression of MED19 in human ovarian cancer tissues correlated with the level of tumor malignancy.
|
22961438 |
2012 |